These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 22081246)

  • 1. Impact of 'LH activity' supplementation on serum progesterone levels during controlled ovarian stimulation: a systematic review.
    Hugues JN
    Hum Reprod; 2012 Jan; 27(1):232-43. PubMed ID: 22081246
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nonsupplemented luteal phase characteristics after the administration of recombinant human chorionic gonadotropin, recombinant luteinizing hormone, or gonadotropin-releasing hormone (GnRH) agonist to induce final oocyte maturation in in vitro fertilization patients after ovarian stimulation with recombinant follicle-stimulating hormone and GnRH antagonist cotreatment.
    Beckers NG; Macklon NS; Eijkemans MJ; Ludwig M; Felberbaum RE; Diedrich K; Bustion S; Loumaye E; Fauser BC
    J Clin Endocrinol Metab; 2003 Sep; 88(9):4186-92. PubMed ID: 12970285
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Basal serum progesterone and history of elevated progesterone on the day of hCG administration are significant predictors of late follicular progesterone elevation in GnRH antagonist IVF cycles.
    Venetis CA; Kolibianakis EM; Bosdou JK; Lainas GT; Sfontouris IA; Tarlatzis BC; Lainas TG
    Hum Reprod; 2016 Aug; 31(8):1859-65. PubMed ID: 27301360
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of endogenous luteinizing hormone serum levels on progesterone elevation on the day of human chorionic gonadotropin administration.
    Hugues JN; Massé-Laroche E; Reboul-Marty J; Boîko O; Meynant C; Cédrin-Durnerin I
    Fertil Steril; 2011 Sep; 96(3):600-4. PubMed ID: 21880277
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recombinant follicle-stimulating hormone and recombinant luteinizing hormone versus recombinant follicle-stimulating hormone alone during GnRH antagonist ovarian stimulation in patients aged ≥35 years: a randomized controlled trial.
    Vuong TN; Phung HT; Ho MT
    Hum Reprod; 2015 May; 30(5):1188-95. PubMed ID: 25740882
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Preovulatory progesterone concentration associates significantly to follicle number and LH concentration but not to pregnancy rate.
    Yding Andersen C; Bungum L; Nyboe Andersen A; Humaidan P
    Reprod Biomed Online; 2011 Aug; 23(2):187-95. PubMed ID: 21665546
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recombinant luteinizing hormone supplementation to recombinant follicle-stimulating hormone induced ovarian hyperstimulation in the GnRH-antagonist multiple-dose protocol.
    Griesinger G; Schultze-Mosgau A; Dafopoulos K; Schroeder A; Schroer A; von Otte S; Hornung D; Diedrich K; Felberbaum R
    Hum Reprod; 2005 May; 20(5):1200-6. PubMed ID: 15665010
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recombinant luteinizing hormone supplementation to recombinant follicle-stimulation hormone during induced ovarian stimulation in the GnRH-agonist protocol: a meta-analysis.
    Oliveira JB; Mauri AL; Petersen CG; Martins AM; Cornicelli J; Cavanha M; Pontes A; Baruffi RL; Franco JG
    J Assist Reprod Genet; 2007; 24(2-3):67-75. PubMed ID: 17195098
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [The influence of exogenous LH/hCG activity on serum progesterone levels on the day of hCG administration in in vitro fertilization].
    Sebag-Peyrelevade S; El Hachem H; Gallot V; Genro VK; Fanchin R
    J Gynecol Obstet Biol Reprod (Paris); 2015 Jun; 44(6):524-31. PubMed ID: 25236690
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of clomiphene citrate during ovarian stimulation on the luteal phase after GnRH agonist trigger.
    Derksen L; Tournaye H; Stoop D; Van Vaerenbergh I; Bourgain C; Polyzos NP; Haentjens P; Blockeel C
    Reprod Biomed Online; 2014 Mar; 28(3):359-68. PubMed ID: 24456700
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effect of LH supplementation to the GnRH antagonist protocol in advanced reproductive ageing women: a prospective randomized controlled study.
    Younis JS; Izhaki I; Ben-Ami M
    Clin Endocrinol (Oxf); 2016 Jan; 84(1):99-106. PubMed ID: 26304041
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bio-equivalent doses of recombinant HCG and recombinant LH during ovarian stimulation result in similar oestradiol output: a randomized controlled study.
    Alsbjerg B; Elbaek HO; Laursen RJ; Povlsen BB; Haahr T; Yding Andersen C; Humaidan P
    Reprod Biomed Online; 2017 Aug; 35(2):232-238. PubMed ID: 28532660
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Controlled ovarian stimulation with exclusive FSH followed by stimulation with hCG alone, FSH alone or hMG.
    Gomes MK; Vieira CS; Moura MD; Manetta LA; Leite SP; Reis RM; Ferriani RA
    Eur J Obstet Gynecol Reprod Biol; 2007 Jan; 130(1):99-106. PubMed ID: 16835006
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Daily low-dose hCG stimulation during the luteal phase combined with GnRHa triggered IVF cycles without exogenous progesterone: a proof of concept trial.
    Andersen CY; Elbaek HO; Alsbjerg B; Laursen RJ; Povlsen BB; Thomsen L; Humaidan P
    Hum Reprod; 2015 Oct; 30(10):2387-95. PubMed ID: 26209535
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Defining the "sweet spot" for administered luteinizing hormone-to-follicle-stimulating hormone gonadotropin ratios during ovarian stimulation to protect against a clinically significant late follicular increase in progesterone: an analysis of 10,280 first in vitro fertilization cycles.
    Werner MD; Forman EJ; Hong KH; Franasiak JM; Molinaro TA; Scott RT
    Fertil Steril; 2014 Nov; 102(5):1312-7. PubMed ID: 25150393
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Luteinizing hormone activity supplementation enhances follicle-stimulating hormone efficacy and improves ovulation induction outcome.
    Filicori M; Cognigni GE; Taraborrelli S; Spettoli D; Ciampaglia W; de Fatis CT; Pocognoli P
    J Clin Endocrinol Metab; 1999 Aug; 84(8):2659-63. PubMed ID: 10443656
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vitro fertilisation. A review of drug therapy and clinical management.
    Jennings JC; Moreland K; Peterson CM
    Drugs; 1996 Sep; 52(3):313-43. PubMed ID: 8875126
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and efficacy of low dose hCG for luteal support after triggering ovulation with a GnRH agonist in cases of polyfollicular development.
    Krause BT; Ohlinger R
    Eur J Obstet Gynecol Reprod Biol; 2006 May; 126(1):87-92. PubMed ID: 16377065
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The origin of serum progesterone during the follicular phase of menotropin-stimulated cycles.
    Eldar-Geva T; Margalioth EJ; Brooks B; Algur N; Zylber-Haran E; Diamant YZ
    Hum Reprod; 1998 Jan; 13(1):9-14. PubMed ID: 9512220
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Vaginal progesterone administration before ovulation induction with exogenous gonadotropins in polycystic ovarian syndrome.
    Buckler HM; Phillips SE; Cameron IT; Healy DL; Burger HG
    J Clin Endocrinol Metab; 1988 Aug; 67(2):300-6. PubMed ID: 3134388
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.